{
    "Figure 1": "Alkyne-containing natural products and drug moleculesA schematic displaying a selection of relevant natural productss and drug moleculess",
    "Figure 2": "Substrate scope of Micratalyzed Cip(s) =- Cisp coupling of terminal allyyes and any lodidesReaction conditions: 10.5 mmol (20.75 mmol) / 20.7 mmol (NCL2) (0.10 mmol) (1.10-phenazanthroline (5.6 mmol), 4.4-Clypyridine M-oxide 0.5mmol (KF 0.75mmol) /2.0-0.6mmol, DIMAC 6.5ml (60.6 mL) / 60.6\u2103, 40.6%,, 48.0% isolated yield.2% at 70\u2109",
    "Figure 3": "Substitute scope of Mactanized Casp-Casp coupling of terminal alyges and any browniesReaction conditions: (0.5mg/mL) 5.0mg/ml S1O2t/ml M2O2/ml N2O3/mL N3O4/mL (N2O5/ml) 1.0-0.0m/ml 1.1-0-2m/mL 0.5mm/ml 0.1m/mol 0.0/mol 1/0.1/ml 2/0/ml D1M/ml DM6/ml 7/0C/mL 10/0M/mL, 4/0-1/2/0m2/mL 1/1/0, 1/4/2, 0.2/2m2, 1.2m3/ml2/1.0mm/mL D2M/mol D1/M2/M3/M4/M5/M6/M7/M8/M9/M10/M11/M12/M13/M14/M15/M16/M17/M18/M19/M20/M21/M22/M23/M24/M25/M26/M27/M28/M29/M30/M31/M32/M34/M35/M36/M37/M38/M39/M40/M41/M42/M43/M44/M45/M46/M48/M50/M51/M52/M53/M54/M55/M56/M57/M58/M59/M60/M61/M62/M63/M64/M65/M66/M67/M68/M69/M70/M71/M72/M73/M74/M75/M76/M78/M79/M80/M81/M82/M83/M84/M85/M86/M87/M88/M89/M90/M91/M92/M93/M94/M95/M96/M97/M98/M99/M101/M102/M104/M105/M106/M107/M108/M109/M110/M112/M113/M114/M115/M116/M117/M118/M129/M130/M131/M132/M134/M135/M136/M137/M138/M139/M140/M150/M170/M175/M176/M180/M171/M172/M190/M191/M192/M194/M195/M",
    "Figure 5": "Selectivity of Ni-catalyzed Clp3-Cisp3-(Cisp) coupling of fiodide vs. bromideStandard conditions: any halide (0.5 mmol), terminal alkynes(0.75 mmol), NIC(2) (10 mol (%)), 1,10-phenanthroline (15 mol %), 4-CN-pyryidine N-oxide (0,75 mmol) (KF (0 75 mmol), Zn(0,6 mmol),DMAC (5 mL) N2, 48 h, isolated yield",
    "Figure 6": "Mechanistic studies(A) N(COD2), (0.5 mmol), (1.10-phenanthroline (0,5 mmol),(4.0.55 mmol), super dry THF (7 mL).(B) 4(0.05 mmol], (5.0-75 mmol), 22 (10.0 mmol), 4-CN-cydridine N-oxide (0 75 mmol), KF 0.75 mmol) Zn(0,06 mmol), DMA(5.5 mL), 70\u2103, N2, 48h, isolated yield.(C) 22 (1 mmol), 51(0-15 mmol),4-CN+pyyridine N-oxide [0.15 mmol], KF (0:15 mmol). DMAC(1 mL) 70\u2143,N2,48h,isolated yield.(D) 4[0.45 mmol], 5[0- 75 mmol], NIC(2,10 mol (%),, 1,0-phenanthroline [15 mol%) KF0.7 mmol), Zn (0-6 mmol), KO(Bu) 0,75 mmol], DMAac(5mL), 70C, 48H, isolated yield.(E) 5[1.075 mmol], KO(Bu) 0.7.75 mmoll) (left equation), 4[5 mmol], NIC(1.0 mol%) 1,10-phenanthanthaline (15 mol), 1-10.phenanthanoline (15 mL), Kf (0\u00b775 mmol). Zn.(0.6 mmol], Zn-(0.06 mmol], 70\u2043, 48 h, isolated yields(right equation)",
    "Figure 7": "DFT-calculated free-energy profilesProfiles of N-catalyzed Sonogastina coupling and the optimized geometries of transition states",
    "Figure A": "Product transformation of the Mcacalyzed Cisp-Cisp coupling and gramscalereaction",
    "Scheme 1": "Development of transition-catalyzed Sonogashira reactions(A) Single palladium catalyzed Soneogashirra reactions: two-step method, air - and moisture-sensitive lithium acetylides are required to be prepared inadvance.(B) Single copper catalyzed Songogashiri reactions: high temperature promoted reactions.(C) This work: single nickel catalyzed Soongashiri reactions: mild reaction conditions"
}